Docoh
Loading...

70 results

Filter options loading...
Top filers
Top filing types
Recent filing years
DEFA14A
PCSA Processa Pharmaceuticals Inc
20 Sep 21
Additional proxy soliciting materials
2:53pm
with preliminary materials: Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which
DEF 14A
PCSA Processa Pharmaceuticals Inc
20 Sep 21
Definitive proxy
2:51pm
with preliminary materials: Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting
PRE 14A
PCSA Processa Pharmaceuticals Inc
1 Sep 21
Preliminary proxy
4:46pm
with preliminary materials: Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which
10-Q
2021 Q2
PCSA Processa Pharmaceuticals Inc
12 Aug 21
Quarterly report
4:01pm
will be reduced for the effect of non-deductibility of the amortization of the intangible asset and may be offset by the deferred tax assets resulting from net … benefit from our projected ordinary tax loss, which can be used to offset the deferred tax liabilities related to the intangible assets and resulted
10-Q
2021 Q1
PCSA Processa Pharmaceuticals Inc
13 May 21
Quarterly report
4:30pm
for the effect of non-deductibility of the amortization of the intangible asset and may be offset by the deferred tax assets resulting from net operating tax … our projected ordinary tax loss, which can be used to offset the deferred tax liabilities related to the intangible assets and resulted
DEFA14A
PCSA Processa Pharmaceuticals Inc
26 Apr 21
Additional proxy soliciting materials
4:06pm
with preliminary materials: Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which
DEF 14A
PCSA Processa Pharmaceuticals Inc
22 Apr 21
Definitive proxy
2:00pm
with preliminary materials: Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which
10-K
2020 FY
PCSA Processa Pharmaceuticals Inc
24 Mar 21
Annual report
8:00pm
to specific pharmaceutical products to offset the loss of patent protection due to the lengthy testing and clinical trials these products require … in 2019 related to an increase in stock-based compensation of $749,830, which was offset by a decrease in salaries and related benefits of $87,738
10-Q
2020 Q3
PCSA Processa Pharmaceuticals Inc
12 Nov 20
Quarterly report
4:01pm
of the intangible asset and may be offset by the deferred tax assets resulting from net operating tax losses. Under ASC 740-270 Income Taxes – Interim Reporting, we … before income taxes. Based on the projection, we expect to recognize the tax benefit from our projected ordinary tax loss, which can be used to offset
424B4
PCSA Processa Pharmaceuticals Inc
5 Oct 20
Prospectus supplement with pricing info
4:16pm
-deductibility of the amortization of the intangible asset for the current period. Additionally, the liability is being offset for the deferred tax assets … and licenses of approximately $25,000. These decreases were offset by an increase in insurance and telephone expenses of $3,800 and increased payroll
S-1/A
PCSA Processa Pharmaceuticals Inc
30 Sep 20
IPO registration (amended)
4:06pm
, the liability is being offset for the deferred tax assets resulting from our net taxable operating losses. Comparison of the three and six months ended June … costs such as office expenses, travel, and taxes and licenses of approximately $25,000. These decreases were offset by an increase in insurance
S-1/A
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
. Additionally, the liability is being offset for the deferred tax assets resulting from our net taxable operating losses. Comparison of the three and six … administrative costs such as office expenses, travel, and taxes and licenses of approximately $25,000. These decreases were offset by an increase
S-1/A
EX-2.1
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
indemnification for any loss from John P. McGrain pursuant to this Section 7.06, HUWX shall first credit and offset against any such claim the proceeds received
S-1/A
EX-10.1
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
), such expiration, termination or settlement shall not reduce (or otherwise offset) the number of shares of Common Stock that may be issued pursuant to the Plan
10-Q
2020 Q2
PCSA Processa Pharmaceuticals Inc
5 Aug 20
Quarterly report
3:32pm
at ways to add a revenue stream to offset some of our expenses but do not currently have any revenue under contract or any immediate sales prospects … of the intangible asset and may be offset by the deferred tax assets resulting from net operating tax losses. Under ACS 740-270 Income Taxes – Interim
S-1/A
PCSA Processa Pharmaceuticals Inc
17 Jul 20
IPO registration (amended)
5:25pm
. Additionally, the liability is being offset for the deferred tax assets resulting from our net taxable operating losses. Comparison of the three months … related to our Phase 2A clinical trial. The increase was offset by a decrease in research and development salaries and benefits of $18,557
DEF 14C
PCSA Processa Pharmaceuticals Inc
27 May 20
Information statement
5:15pm
of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify
PRE 14C
PCSA Processa Pharmaceuticals Inc
15 May 20
Preliminary information
1:50pm
of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify
10-Q
2020 Q1
PCSA Processa Pharmaceuticals Inc
15 May 20
Quarterly report
1:23pm
the LOC Agreement with DKBK. We have not had any revenue since our inception. We are looking at ways to add a revenue stream to offset some of our … of the amortization of the intangible asset and may be offset by the deferred tax assets resulting from net operating tax losses. Under ACS 740-270Income Taxes
10-K
2019 FY
PCSA Processa Pharmaceuticals Inc
5 Mar 20
Annual report
7:00pm
apply to specific pharmaceutical products to offset the loss of patent protection due to the lengthy testing and clinical trials these products require … , which was offset by a decrease in salaries and related benefits of $21,687. The decrease in salaries and related benefits related to one of our research